HER2 Support Group Forums - View Single Post - for those asking about new research about the origins/effects of chemobrain

Lani · 01-01-2008, 12:38 PM

Clin Neurophysiol. 2007 Dec 27 [Epub ahead of print]
ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy.

Kreukels BP, Hamburger HL, de Ruiter MB, van Dam FS, Ridderinkhof KR, Boogerd W, Schagen SB.
Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
OBJECTIVE: Neurocognitive problems that were observed in a number of breast cancer survivors treated with adjuvant chemotherapy initiated a series of EEG studies to examine the neurophysiological basis of these deficits. The aim of the present study was to examine the effects of various regimens of adjuvant chemotherapy on the N1 and P3 component of the event-related potential (ERP) in breast cancer patients 3-6 years after treatment. METHODS: Fifty-three breast cancer patients treated with various chemotherapy regimens were compared to 23 stage I breast cancer patients not treated with chemotherapy. An auditory oddball task was used to study the amplitude, latency and structure of the potential field of the N1 and P3. RESULTS: Patients treated with chemotherapy showed lower P3 amplitudes than patients not treated with chemotherapy. Differences were also observed in P3 latency between patients treated with different chemotherapy regimens. CONCLUSIONS: Our results indicate a general effect of all chemotherapy regimens under study on P3 amplitude and a more specific chemotherapeutic effect on P3 latency. SIGNIFICANCE: The present study provides evidence for the notion that different chemotherapy regimens have different effects on brain functioning.
PMID: 18164658 [PubMed - as supplied by publisher]

Related Links
Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy.
[Breast Cancer Res Treat. 2005]
Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study.
[Clin Breast Cancer. 2006]
Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.
[J Clin Exp Neuropsychol. 2004]

Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia.
[Arch Gen Psychiatry. 2004]

01-01-2008, 12:38 PM	#1
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	for those asking about new research about the origins/effects of chemobrain Clin Neurophysiol. 2007 Dec 27 [Epub ahead of print] ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Kreukels BP, Hamburger HL, de Ruiter MB, van Dam FS, Ridderinkhof KR, Boogerd W, Schagen SB. Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. OBJECTIVE: Neurocognitive problems that were observed in a number of breast cancer survivors treated with adjuvant chemotherapy initiated a series of EEG studies to examine the neurophysiological basis of these deficits. The aim of the present study was to examine the effects of various regimens of adjuvant chemotherapy on the N1 and P3 component of the event-related potential (ERP) in breast cancer patients 3-6 years after treatment. METHODS: Fifty-three breast cancer patients treated with various chemotherapy regimens were compared to 23 stage I breast cancer patients not treated with chemotherapy. An auditory oddball task was used to study the amplitude, latency and structure of the potential field of the N1 and P3. RESULTS: Patients treated with chemotherapy showed lower P3 amplitudes than patients not treated with chemotherapy. Differences were also observed in P3 latency between patients treated with different chemotherapy regimens. CONCLUSIONS: Our results indicate a general effect of all chemotherapy regimens under study on P3 amplitude and a more specific chemotherapeutic effect on P3 latency. SIGNIFICANCE: The present study provides evidence for the notion that different chemotherapy regimens have different effects on brain functioning. PMID: 18164658 [PubMed - as supplied by publisher] Related Links Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. [Breast Cancer Res Treat. 2005] Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. [Clin Breast Cancer. 2006] Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. [J Clin Exp Neuropsychol. 2004] Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia. [Arch Gen Psychiatry. 2004]